Journal article
Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry
BP Yan, AE Ajani, G New, SJ Duffy, O Farouque, J Shaw, M Sebastian, R Lew, A Brennan, N Andrianopoulos, C Reid, DJ Clark
International Journal of Cardiology | ELSEVIER IRELAND LTD | Published : 2008
Abstract
Background: Restenosis rates are low in large coronary vessels ≥ 3.5 mm after bare-metal stent (BMS) implantation. The benefit of drug-eluting stents (DES) in large vessels is not established. Objective: We aim to assess clinical outcomes after deployment of BMS compared to DES in patients with large coronary vessels ≥ 3.5 mm. Methods: We analysed 672 consecutive patients undergoing percutaneous coronary interventions with ≥ 3.5 mm stent implantation in native coronary artery de-novo lesions from the Melbourne Interventional Group (MIG) registry. Baseline characteristics, 30-day and 12-month outcomes of patients receiving BMS were compared to DES. Multivariate analysis was performed to ident..
View full abstractGrants
Funding Acknowledgements
The Melbourne Interventional Group acknowledges funding from Pfizer, Servier, Schering-Plough, Boston Scientific, Johnson & Johnson, Sanofi-Aventis, Biotronik, Astra-Zeneca, Medtronic, and St Jude. These companies do not have access to the data, and do not have the right to review manuscripts before publication. Dr. Duffy's work is supported by a NHMRC Centre of Clinical Research Excellence grant to the Alfred and Baker Medical Unit.